This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
1, 2024 — The Centers for Medicare & Medicaid Services (CMS) have announced a significant adjustment to the Hospital Outpatient Prospective Payment System (HOPPS). However, under the previous reimbursement system, diagnostic radiopharmaceuticals were bundled as “supplies,” limiting access in several ways.
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
As nuclearmedicine therapies gain stature compared to nuclearmedicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclearmedicine technologists means a theranostics center may need to limit its patient volume.
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. ASTRO also supports short-term relief established through the Medicare Patient Access and Practice Stabilization Act, which would eliminate the looming 2.8%
The Society of NuclearMedicine and Molecular Imaging (SNMMI) presented its 2025 Legislative Champion Award to Representatives Neal Dunn, MD, and Ami Bera, MD. Centers for Medicare and Medicaid (CMS) to update the Hospital Outpatient Prospective Payment System (HOPPS) in 2025 by unbundling radiopharmaceuticals.
Nuclear cardiologists could see significant reductions in Medicare reimbursements in 2025, according to a leading expert. Nuclear cardiologists need to be aware of the potential negative financial impact and plan accordingly, Phillips said. Despite a proposal by the U.S.
Scientific Paper of the Year Advanced Practice Provider Procedures Commonly Performed in Interventional Radiology: Medicare Volume Trends From 2010 to 2021. Luthria, et al, Journal of NuclearMedicine , October 26, 2023. Radiologist Workforce Attrition from 2019 to 2024: A National Medicare Analysis.
Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PET scans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime. Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions.
30, 2025 Earlier this month, the Society of NuclearMedicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,
By the end of June 2023, commercial production across the country will be underway at the 31 PETNET radiopharmacies Blue Earth Diagnostics included in its New Drug Application for POSLUMA, marking a record number of sites authorized for the manufacturing of a radiopharmaceutical upon its initial FDA approval.
The Society of NuclearMedicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released new appropriate use criteria for brain PET imaging of amyloid and tau pathology related to cognitive impairment and Alzheimers disease. Since then, the U.S. There are three PET radiotracers labeled with F-18 approved by the U.S.
8, 2025 The Society of NuclearMedicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Tue, 01/14/2025 - 16:48 Jan.8, Since then, the U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content